Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
12.61
+1.01 (8.71%)
Aug 19, 2026, 9:57 AM EDT - Market open
Intellia Therapeutics Revenue
Intellia Therapeutics had revenue of $7.66M in the quarter ending June 30, 2026, a decrease of -46.23%. This brings the company's revenue in the last twelve months to $59.51M, up 12.58% year-over-year. In the year 2025, Intellia Therapeutics had annual revenue of $67.67M with 16.92% growth.
Revenue (ttm)
$59.51M
Revenue Growth
+12.58%
P/S Ratio
29.32
Revenue / Employee
$157,841
Employees
377
Market Cap
1.77B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 67.67M | 9.79M | 16.92% |
| Dec 31, 2024 | 57.88M | 21.60M | 59.55% |
| Dec 31, 2023 | 36.28M | -15.85M | -30.40% |
| Dec 31, 2022 | 52.12M | 19.07M | 57.69% |
| Dec 31, 2021 | 33.05M | -24.94M | -43.01% |
| Dec 31, 2020 | 57.99M | 14.89M | 34.55% |
| Dec 31, 2019 | 43.10M | 12.67M | 41.63% |
| Dec 31, 2018 | 30.43M | 4.32M | 16.53% |
| Dec 31, 2017 | 26.12M | 9.64M | 58.49% |
| Dec 31, 2016 | 16.48M | 10.44M | 172.65% |
| Dec 31, 2015 | 6.04M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.68B |
| Immunocore Holdings | 430.78M |
| AnaptysBio | 232.39M |
| Xencor | 104.97M |
| Ascentage Pharma Group International | 82.08M |
| Recursion Pharmaceuticals | 54.86M |
| Absci | 1.56M |
NTLA News
- 11 days ago - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 12 days ago - Intellia Therapeutics upgraded to Outperform from In Line at Evercore ISI - TheFly
- 12 days ago - Intellia Therapeutics upgraded to Outperform from In Line at Evercore ISI - TheFly
- 13 days ago - Intellia Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 13 days ago - Intellia Therapeutics Earnings release: Q2 2026 - Filings
- 13 days ago - Intellia Therapeutics Quarterly report: Q2 2026 - Filings
- 13 days ago - Intellia Therapeutics reports Q2 EPS (80c), consensus (78c) - TheFly
- 13 days ago - Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - GlobeNewsWire